3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
28
Phase 2
23
Phase NA
3
Phase 1/2
2
Phase 1
2
Phase 2/3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Leukemia
6
Lymphoma
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Osteosarcoma
2
Leukemia, T-Cell
2
Leukemia, Myeloid, Acute
2
Gestational Trophoblastic Disease
2
Burkitt Lymphoma
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Sarcoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Neoplasms, Connective and Soft Tissue
1
Neoplasms, Connective Tissue
1
Neoplasm, Residual
1
Myelodysplastic Syndromes
1
Lymphoma, Follicular
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Large Granular Lymphocytic
1
Leukemia, Biphenotypic, Acute
1
Drug-Related Side Effects and Adverse Reactions
1
Breast Neoplasms
1
Bone Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Anemia, Refractory
1
Interventions
Capecitabine
16
Paclitaxel
12
Docetaxel
10
Cyclophosphamide
10
Epirubicin
8
Gemcitabine
7
Letrozole
6
Doxorubicin
6
Carboplatin
6
Trastuzumab
5
Vinorelbine
4
Cisplatin
4
pertuzumab
3
exemestane
3
Neoadjuvant Therapy
3
Drug Therapy
3
Ado-Trastuzumab Emtansine
3
AC protocol
3
130-nm albumin-bound paclitaxel
3
apatinib
2
Zoledronic Acid
2
Thiotepa
2
Taxes
2
Tamoxifen
2
Standard of Care
2
Radiosurgery
2
Melatonin
2
Lapatinib
2
Injections
2
Goserelin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Breast Neoplasms
×
Methotrexate
×
Clear all
NCT01204437
2016-02-10
ICE-II
GBG Forschungs GmbH
Phase 2/3
Completed
400 enrolled